Alliance Global Partners analyst Ben Haynor downgraded Heska to Neutral from Buy with a price target of $120, down from $129, after the company entered into a definitive agreement to be acquired by Mars for $120 per share. The analyst views the combination of Mars’ existing Antech veterinary reference lab business along with Heska’s point-of-care diagnostic offerings as "highly complementary." The firm expects the transaction to be completed on a timeline consistent with closing earlier in the second half of the year rather than later.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HSKA:
- Mars to Acquire Heska, Global Provider of Advanced Veterinary Diagnostic and Specialty Solutions
- Mars to acquire Heska for $120.00 per share
- Heska price target lowered to $150 from $165 at Piper Sandler
- Heska price target raised to $129 from $119 at Alliance Global Partners
- Heska Corporation Reports Fourth Quarter and Full Year 2022 Results